Health Economics›Classical Hodgkin lymphoma pediatric›Consolidation after upfront therapy

Consolidation after upfront therapy

Classical Hodgkin lymphoma pediatric · 3 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
COPDAC Variant #01	—	R 4 424	28d	—	—	~2	~R 8 848 indirect	—
C-MOPP Variant #01 Partial	—	R 946	28d	—	—	~2	~R 1 892 indirect	—
Radiation therapy N/A - radiation	—	—	49d	~25.5 mo	~10.6 mo	—	—	24

3 of 3 regimens shown